Bone Morphogenetic Protein Receptor 2 (BMPR2)/TAK1-d signaling regulates the phosphorylation of Ser76 in MCUb to control mitochondrial Ca2+ levels and survival of cancer cells

Inside every living cell, tiny power plants called mitochondria work tirelessly to generate the energy required for life. To function correctly, these power plants need a precise balance of calcium, a mineral that acts as a vital signal for energy production. However, this balance is fragile. If too much calcium floods into the mitochondria, the power plants can become overwhelmed, leading to a cascade of events that shuts down energy production and triggers the cell to self-destruct. This delicate control system is a frequent target in the fight against cancer, as researchers look for ways to force malignant cells to overload their own power plants and die, while leaving healthy cells unharmed.

Scientists have long known that a specific protein called Bone Morphogenetic Protein Receptor 2, or BMPR2, plays a role in how cells manage this calcium. In healthy development, this receptor helps guide cells, but in many cancers, it remains active and helps tumor cells survive. A team of researchers at Rutgers University recently investigated exactly how this receptor controls the flow of calcium into the mitochondria. They discovered that BMPR2 acts like a gatekeeper, working through a secondary protein to keep the calcium gates closed. When the researchers blocked this receptor, the gates swung open, allowing a flood of calcium to enter the mitochondria. This influx was particularly deadly when combined with existing cancer drugs, suggesting a new way to weaken tumors.

The researchers focused their study on two types of cancer cells: those from non-small cell lung cancer and various types of leukemia. They used a specific chemical compound, known as JL189, to block the BMPR2 receptor. When they treated the cancer cells with this blocker alone, the cells began to take up more calcium. However, the real breakthrough came when they combined this blocker with another class of drugs known as BCL-2 inhibitors, which are already used to treat blood cancers. These BCL-2 inhibitors work by removing a safety mechanism that prevents cells from dying. When the researchers paired the BMPR2 blocker with the BCL-2 inhibitor, the cancer cells did not just die; they died much faster and more completely than with either drug alone. This effect was especially strong in leukemia cells, including those that had developed resistance to standard chemotherapy.

To understand why this combination was so effective, the team looked closely at the machinery inside the mitochondria. They found that the BMPR2 receptor normally signals a protein called TAK1-d to phosphorylate, or chemically tag, a specific part of a protein called MCUb. Think of MCUb as a brake pedal for the calcium intake system. When BMPR2 is active, it tells the cell to press this brake, keeping calcium levels low and the cell alive. The researchers found that when they blocked BMPR2, this chemical tag was removed, releasing the brake. Without the brake, the mitochondria began to gulp down calcium at an alarming rate. This process was further amplified by reactive oxygen species, which are unstable molecules that naturally increase when cells are under stress or treated with certain drugs. The researchers showed that if they scavenged these unstable molecules, the calcium overload and cell death were significantly reduced, proving that the two processes were linked.

The study also revealed a fascinating detail about how the cell manages this system. The researchers identified that the protein being tagged was not just the main calcium channel, but a specific variant called MCUb, which acts as a dominant-negative regulator, essentially acting as a counterweight to the main channel. They discovered that the receptor specifically tags a spot on this MCUb protein, known as Ser76. When this spot is tagged, the channel stays closed. When the tag is removed by blocking the receptor, the channel opens. The team confirmed this by creating cells where the MCUb protein could not be tagged at all; these cells died much more easily when treated with the combination therapy, proving that the tagging mechanism is a critical survival switch for the cancer cells.

Interestingly, the effects of this mechanism varied between different types of cancer. In lung cancer cells, blocking the receptor increased the energy production of the mitochondria, making the cells more active. In leukemia cells, however, the same action led to a collapse in energy production and rapid cell death. This suggests that the way cells use this calcium control system depends heavily on their specific type and environment. The researchers also found that leukemia cells with a specific mutation in a gene called p53, which often makes them resistant to other treatments, were highly sensitive to this new combination. This is significant because p53-mutated leukemia is notoriously difficult to treat, often leaving patients with very few options.

While the results in the lab were promising, the researchers were careful to note the limitations of their current tools. The chemical compound they used, JL189, worked well in a dish but had poor properties for use in living animals. It was cleared from the bloodstream too quickly and had potential side effects on the heart and liver enzymes. Consequently, when they tried to test the combination in mice with lung tumors, the drug did not perform as well as it did in the cell cultures, and the study in a mouse model of leukemia had to be stopped due to toxicity. The researchers concluded that while the biological mechanism is sound and the potential for a new treatment is real, a better version of the drug needs to be developed before this approach can be tested in patients.

The study highlights a complex and elegant system of cellular regulation. It shows that cancer cells rely on a specific chemical tag on a calcium regulator to stay alive. By removing that tag, scientists can force the cell's power plants to overload, leading to the cell's destruction. This mechanism appears to be a universal vulnerability in certain cancers, particularly those that have become resistant to other therapies. The findings suggest that targeting the BMPR2 receptor could be a powerful strategy to sensitize cancer cells to existing treatments, turning a cell's own survival mechanisms against it. The path forward involves refining the drug to make it safe for human use, but the discovery of this specific calcium control switch offers a clear and concrete new direction for fighting some of the most stubborn forms of cancer.